Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	4.91B
Revenue (ttm)	875.14M
Net Income (ttm)	318.90M
Shares Out	77.87M
EPS (ttm)	4.03
PE Ratio	15.62
Forward PE	n/a
Dividend	3.00 (4.77%)
Ex-Dividend Date	Oct 25, 2024

Volume	1,131,333
Average Volume	924,377
Open	62.88
Previous Close	62.85
Day's Range	62.40 - 63.56
52-Week Range	45.17 - 84.72
Beta	0.42
RSI	42.58
Earnings Date	Apr 29, 2025

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 969
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2024, Hangzhou Alltest Biotech's revenue was 866.58 million, an increase of 14.83% compared to the previous year's 754.70 million. Earnings were 302.47 million, an increase of 67.50%.